Molecular mechanisms of oncogenesis gliomas brain: literature review
Keywords:
brain tumors, gliomas, molecular targets, apoptosisAbstract
The increasingly rapid pace of discovery in molecular biology, biochemistry and genetics continues to produce many new targets for cancer therapy. The aim of the present review was to focus our attention on effective, selective molecular targets for new chemotherapy of malignant brain tumors, pecullary intracerebral glioma, and to apply new molecular knowledge to enhance the effectiveness and specificity of existing active agents. Such finding form the basis for the development of drugs for the complex care of glioma patients.References
1. Dmitrenko VV. Identifikatsiya novykh opukholespetsificheskikh molekulyarnykh markerov metodami ekspressionnoy genetiki [Identification of new molecular markers of tumor expression using genetics methods]. Eksperim. Onkologia. 1999;21:97-103. Russian.
2. Dmitrenko VV, Garyfulin OM, Zozulyua YuP, Kavsan VM. Zminy ekspresiyi heniv v astrotsytnykh pukhlynakh holovnoho mozku lyudyny [Changes in gene expression in human astrotsyt brain tumors]. Eksperim. Onkologia. 1998;20:191-7. Ukrainian.
3. Zozulia IuA, Gridina NIa. [The molecular genetics of gliomas and the outlook for molecular neurosurgery]. Zh Vopr Neirokhir Im NN Burdenko. 1998;4:45-51. Russian. [PubMed]
4. Korshunov AG, Golanov AV, Sycheva RV, Pronin IN. [The prognostic importance of cancer-associated proteins and apoptosis in glioblastomas of the cerebral hemispheres]. Zh Vopr Neirokhir Im NN Burdenko. 1999;1:3-7. Russian. [PubMed]
5. Fil’chenkov AA. Tsitokiny supersemeystva EFR i onkogenez [Cytokines EGF superfamily and oncogenesis]. Eksperim. Onkologia. 1998;20(2):83-108. Russian.
6. Fil’chenkov AA, Stojka RS. Apoptoz i rak [Apoptosis and Cancer]. In: Bykorez Ai., editor. Kiev: Morion; 1999. Russian.
7. Ames BN, Gold LS. Chemical carcinogenesis: too many rodent carcinogens. Proc Natl Acad Sci USA. 1990;87(19):7772-6. [PubMed] [CrossRef]
8. Bakshi A, Nag TC, Wadhwa S, Mahapatra AK, Sarkar C. The expression of nitric oxide synthase in human brain tumouros and peritumoral areas. J Neurol Sci. 1998;155(2):196-203. [PubMed] [CrossRef]
9. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life span by introduction of telomerase into normal human cells. Science. 1998;279(5349):349-352. [PubMed]
10. Castro GC, Ravina M, Castro V, Salido EC. Expression of epidermal growth factor receptor (protooncogene c-erb B-1) and estrogen receptor in human breast carcinoma. An immunocytochemical study of 70 cases. Arch Gynecol Obstet. 1993;252(4):169-177. [PubMed]
11. Chung DH, Lee JI, Kook MC, Kim JR, Kim SH, Choi EY, Park SH, Song HG. ILK (beta-1-integrin-linked protein kinase): a novel immunohistochemical marker for Ewing’s sarcoma and primitive neuroectodermal tumour. Virchows Arch. 1998;443(2):113-7. [PubMed] [CrossRef]
12. Clark EA, Brugge JS. Integrins and signal transduction pathways the road taken. Science. 1995;268(5208):233-9. [PubMed] [CrossRef]
13. Cockett M.. Murphy G, Birch ML, O'Connell JP, Crabbe T, Millican AT, Hart IR, Docherty AJ. Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp. 1998;63:295-313. [PubMed]
14. Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH. Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. Neurosurgery. 1995;37(2):246-54. [PubMed]
15. De Clerck YA, Shimada H, Taylor SM, Langley KE. Matrix metalloproteinases and their inhibitors in tumor progression. Ann NY Acad Sci. 1994;732:222-32. [PubMed] [CrossRef]
16. Della Ragione F, Borriello A, Giordani J, Iolascon A. Cell division cycle alteration in human malignancies. Le Journal du Cancer. 1997;10(3):151-6. http://cat.inist.fr/?aModele=afficheN&cpsidt=2705356.
17. Dirks PB, Hubbard SL, Murakami K, Rutka JT. Cyclin and cyclin-dependent kinase expression in human astrocytoma cells lines. J Neuropathol Exp Neurol 1997;56(3):291-300. [PubMed] [CrossRef]
18. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146(5):1029-39. [PubMed]
19. El-Obeid A, Bongcam-Rudloff E, Sorby M, Ostman A, Nistér M, Westermark B. Cell scattering and migration induced by autocrine transforming growth factor alpha in human glioma cell in vitro. Cancer Res. 1997;57(24):5598-604. [PubMed]
20. Engelhard H, Narang C, Homer R, Duncan H. Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma; In vitro and in vivo studies of uptake effects and toxicity. Biochem Biophys Res Commun. 1996;227(2):Р.400-5. [PubMed] [CrossRef]
21. Finn PE, Bjerkvig R, Pilkington GI. The role of growth factors in the malignant and invasive progression of intrinsic brain tumours. Anticancer Res. 1997;17(6B):4163-72. [PubMed]
22. Green DR, McGahon A, Martin SM. Regulation apoptosis by oncogenes. J Cell Biochem. 1996;60:33-8. [PubMed] [CrossRef]
23. Harvey P, Warn A, Dobbin S, Arakaki N, Daikuhara YJ, Warn RM. Expression of НGF/SF in mesothelioma cell lines and it’s effects on cell motility, proliferation and morphology. Brit J Cancer. 1998;77(7):1052-9. [PubMed] [CrossRef]
24. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC. Database of p53 gene somatic mutation in human tumors and cell lines. Nucl Acids Res. 1994;22(17):3551-5. [PubMed]
25. Iadecola C, Zhang F, Casey R, Clark HB, Ross ME. Inducible nitric oxide synthase gene expression in vascular cell after transsient focal cerebral ischemia. Stroke. 1996;27(8):1373-80. [PubMed] [CrossRef]
26. Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci. 1997;20(3):132-9. [PubMed] [CrossRef]
27. Isner JM, Asahara T. Therapeutic angiogenesis. Front Biosci. 1998;3:49-69. [PubMed]
28. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC, Moncada S. Role of nitric oxide in tumor growth. Proc Natl Acad Sci USA. 1995;92(10):4392-6. [PubMed]
29. Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol. 1998;49(2):189-96. [PubMed] [CrossRef]
30. Kajita Y, Takayasu M, Dietrich HH, Dacey RG. Jr. Possible role of nitric oxide in autoregulatory response in rat intracerebral arterioles. Neurosurgery. 1998;42(4):834-42. [PubMed] [CrossRef]
31. Kakunaga T. The role of cell division in the malignant transformation of mouse cell treated with 3-methylcholantrence. Cancer Res. 1975;35(7):1637-42. [PubMed]
32. Kashtan MB, Onyekwere O, Sidrannsky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:23, Pt.1:6304-11. [PubMed]
33. Kerr FR, Winterfold CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994;73(8):2013-26. [PubMed] [CrossRef]
34. King GR, Kraus MH, Aaronson SA. Amplification of novel v-erb B-related gene in a human mamary carcinoma. Science. 1985;229(4717):974-6. [PubMed] [CrossRef]
35. King KL, Cildlowski JA. Cell cycle and apoptosis 1. Ann Rev Physiol. 1998;60:601-17. [PubMed] [CrossRef]
36. Kirsch M, Strasser J, Allende R, Bello L, Zhang J, Black PM. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res. 1998;58(20):4654-9. [PubMed]
37. Kondo V, Kondo S, Tanaka Y, Haqqi T, Barna BP, Cowell JK. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatininduced apoptosis. Oncogene. 1998;1(17):2243-8. [PubMed] [CrossRef]
38. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323-31. [PubMed] [CrossRef]
39. Ligon AH, Pershouse MA, Jasser SA, Yung WK, Steck PA. Identification of a novel gene product RIG, that is down-regulated in human glioblastoma. Oncogene. 1997;14(9):1075-81. [PubMed] [CrossRef]
40. Maass JD, Gottschlich S, Goerogh T, Lippert BM, Werner JA. Head and neck cancer and p53-immunogenicity: 8th Hamburger Symp.: Tumor Markers. Anticancer Res. 1997;17(4B):2873-4. [PubMed]
41. Mareel M, Berx G, Van Roy F, Bracke M. Cadherin/catenin complex: a target for antiinvasive therapy? J Cell Biochem. 1996;61(4):524-30. [PubMed] [CrossRef]
42. Massague J, Pandiella A. Membrane-anchored growth factors. Annu Rev Biochem. 1993;62:515-41. [PubMed] [CrossRef]
43. Miyaji K, Tani E, Nakano A, Ikemoto H, Kaba K. Inhibition by fibroblast by 5’-methyltioadenosine of cell growth and tyrosine kinase activity stimulated by fibroblast growth factor receptor in human gliomas. J Neurosurg. 1995;83(4):690-7. [PubMed] [CrossRef]
44. Moll UM, La Quaglia M, Benard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA. 1995;92(10):4407-11. [PubMed] [CrossRef]
45. Morrison RS, Yamaguchi F, Bruner J, Tang M, McKeehan W, Berger MS. Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res. 1994;54(10):2794-9. [PubMed]
46. Nobori T, Takabayashi K, Tran Ph, Orvis L, Batova A, Yu AL, Carson DA. Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancer. Proc Natl Acad Sci USA. 1996;93(12):6203-8. [PubMed] [CrossRef]
47. O’Reily MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277-85. [PubMed] [CrossRef]
48. Pietenpol JA, Lengauer ChJ, Kinzler KW, Vogelstein B. Mammalian cells resistant to tumor suppressor genes. Proc Natl Acad Sci USA. 1996;93(16):8390-4. [PubMed] [CrossRef]
49. Pitot HC, Beer D, Hendrich S. Multistage carcinogenesis: the phenomenon underlying the theories. In: Estabrook RW, Lindenlaub EL., editors. Theories of Carcinogenesis. Washington: Hemisphere Publ.; 1987. p.159-91.
50. Phylchenkov A, Kudryavets Yu. Transforming growth factor-alpha and lymphoid malignancies: a possible pathological paracrine role. Eur Cytokine News. 1996;7:592.
51. Sager R. Expression genetics in cancer: shifting to focus from DNA to RNA. Proc Natl Acad Sci USA. 1997;94(3):952-5. [PubMed] [CrossRef]
52. Salcman M, Scholtz H, Kaplan RS, Kulik S. Long-term survival in patients with malignant astrocytoma. Neurosurgery. 1994;34(2):213-20. [PubMed] [CrossRef]
53. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA. The neu oncogene: a erb-B-related gene encoding a 185,000-Mr tumor antigen. Nature. 1984;312(5994):513-6. [PubMed] [CrossRef]
54. Sehgal A, Keener C, Boynton AL, Young RF, Vermeulen SS, Yonemura KS, Kohler EP, Aldape HC, Simrell CR, Murphy GP. Characterization of C4-2 as a tumor-suppressor gene in human brain tumors. J Surg Oncol. 1997;64(2):102-8. [PubMed] [CrossRef]
55. Sehgal A, Boynton AL, Young RF, Vermeulen SS, Yonemura KS, Kohler EP, Aldape HC, Simrell CR, Murphy GP. Cell adhession molecule Nr-Cam in over-expressed in human brain tumors. Int J Cancer. 1998;76(2):451-8. [PubMed] [CrossRef]
56. Sehgal A, Boynton AL, Young R, Vermeulen SS, Yonemura KS, Kohler EP, Aldape HC, Simrell CR, Murphy GP.Applification of the differential hybridization of Atlas Human expression arrays technique in the identification of differentially expressed genes in human glioblastoma multiforme tumor tissue. J Surg Oncol. 1998;67(4):234-41. [PubMed] [CrossRef]
57. Shapiro G.I., Rollins B.J. p16INR4A as a human tumor suppressor. Biochem Biophys Acta Rev Cancer. 1996;1242(3):165-9. [PubMed] [CrossRef]
58. Toi M, Kondo Sh, Suzuki H, Yamamoto Y, Inada K, Imazawa T, Taniguchi T, Tominaga T. et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer. 1996;77(6):1101-6. [PubMed] [CrossRef]
59. Tsai JC, Galdman CK, Gillespie GV. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB and EFGF. J Neurosurg. 1995;82(5):864-73. [PubMed] [CrossRef]
60. Van Meir EG, Roemer K, Diserens AC, Kikuchi T, Rempel SA, Haas M, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK. Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells. Proc Natl Acad Sci USA. 1995;92(4):1008-12. [PubMed] [CrossRef]
61. Van der Geer P., Hunter T., Lindberg R.A. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol. 1994;10:251-337. [PubMed] [CrossRef]
62. Whittle JR, Collins F, Kelly PA, Ritchie I, Ironside JW. Nitric oxide synthase is expressed in experemental malignant glioma and influences tumor malignant glioma and influences tumour blood flow. Acta Neurochir (Wien). 1996;7:870-6. [PubMed] [CrossRef]
63. Wu C, Keightley SY, Loung-Hagesteijn C. Radeva G, Coppolino M, Goicoechea S, McDonald JA, Dedhar S. Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. J Biol Chem. 1998;273(1):528-36. [PubMed] [CrossRef]
64. Yahanda AM, Bruner JM, Donehower LA, Morrison RS. Astrocytes derived from p53 deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol Cell Biol. 1995;15(8):4249-59. [PubMed]
65. Zimmerman M, Seifert V. Endothelial and Subarachnoid Hemorrhage: an overview. Neurosurgery. 1998;43(4):863-76. [PubMed] [CrossRef]
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2000 Yuriy Zozulya, L. Senko
This work is licensed under a Creative Commons Attribution 4.0 International License.
Ukrainian Neurosurgical Journal abides by the CREATIVE COMMONS copyright rights and permissions for open access journals.
Authors, who are published in this Journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the Journal under the terms of Creative Commons Attribution License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this Journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form of which it has been published by the Journal (for example, to upload the work to the online storage of the Journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this Journal is included.
